Metagenomi, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Metagenomi, Inc.

Upcoming Lead Plaintiff Deadline is November 25, 2024 NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP (" Wolf Haldenstein ") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of persons and entities that purchased or otherwise acquired Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX ) securities between February 6, 2024 and September 26, 2024 , inclusive (the "Class Period").

CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASE A ll investors who purchased shares and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.

whafh.com . If you have incurred losses, you may, no later than November 25, 2024 , request that the Court appoint you as the lead plaintiff of the proposed class.

Please contact Wolf Haldenstein to learn more about your rights. On or around February 9, 2024 , Metagenomi conducted its initial public offering ("IPO") of 6.25 million shares of common stock priced at $15.

00 per share. Then, on May 1, 2024 , Metagenomi announced that it and Moderna, Inc. had "mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1)," and that " the rights to develop the PH1 pro-gram, as well as all other rights granted under the.